This study is for adults with a type of blood cancer called AML (Acute Myeloid Leukemia) that didn't get better after two, three, or four previous treatments. The study compares two groups: one gets a new drug, **DFP-10917**, through an IV (a tube into a vein) for 14 days, and the other gets one of several standard treatments based on their past treatments. The goal is to see which treatment helps more people fully recover and for how long.

Key Points for Patients:

• **Duration**: Treatments are given in 28-day cycles.
• **Eligibility**: Must be 18 or older with previous unsuccessful treatments for AML.
• **Risks**: Possible side effects include reactions from the drugs used.

To join, you need to have a confirmed AML diagnosis, be in good enough health (based on specific lab tests), and agree to use birth control if you can have children. Make sure to discuss with your doctor to see if this study is a good fit for you.